

Declaration of Interests Register

Technology Appraisal Committee A

Publication Date: 20/11/2019

Topic: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Dr Nigel Bundred	Clinical expert	Direct - financial	He has received remuneration for attending PUMA advisory boards	-	April 2019	-	declare and participate in the appraisal. Chair Jane Adam.